期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 31, 期 4, 页码 589-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2017.04.007
关键词
Chronic myeloid leukemia (CML); Tyrosine kinase inhibitor (TKI); BCR-ABL1; Treatment-free remission (TFR); Drug resistance; Mutation
资金
- NIH [1R01CA178397-01, 1R21CA205936-01]
- V Foundation for Cancer Research
- Hope Foundation
- University of Utah
Chronic myeloid leukemia is increasingly viewed as a chronic illness; most patients have a life expectancy close to that of the general population. Despite progress made using BCR-ABL1 tyrosine kinase inhibitors (TKIs), drug resistance via BCR-ABL1 dependent and BCR-ABL1 independent mechanisms continues to be an issue. BCR-ABL1 dependent resistance is primarily mediated through oncoprotein kinase domain mutations and usually results in overt resistance to TKIs. However, BCR-ABL1 independent resistance in the setting of effective BCR-ABL1 inhibition is recognized as a major contributor to minimal residual disease. Efforts to eradicate persistent leukemic stem cells have focused on combination therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据